Compare ADMA Biologics Inc (ADMA) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs BridgeBio Pharma Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is far larger — about 7.6× ADMA Biologics Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | BBIO | |
|---|---|---|
Market Cap | $2.18B | $16.61B |
Sector | Health | Health |
52-Week High | $20.38 | $90.17 |
52-Week Low | $7.60 | $47.29 |
Enterprise Value | $2.25B | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
